Thibaut du Fayet
Follow this person across linked issuers and source filings.
Companies in disclosed relationships
1
Public filings
1
Net disclosed balance
€33,465.82
Latest filing
4 Jul 2023
Historical timing
Explore the full rankingFrance · 730 days · 13-week horizon · All directions
Timing data could not be loaded. Retry this section without leaving the research page.
Recent filings
Each filing stays linked to the issuer and the evidence behind the normalized values.
| Date | Issuer | Type | Gross reported value (EUR) | Open |
|---|---|---|---|---|
| 4 Jul 2023 | ERYTECH PHARMA | InitialEffective | Buy €33,465.82 Buy/sale net: €33,465.82 | Open |
Gross reported value (EUR)
€33,465.82
Supporting information
ERYTECH PHARMA
InitialEffective
Buy/sale net: €33,465.82
Network and companies
Explore verified issuer connections and select a company to inspect the reported role and evidence.
- PHAXIAM THERAPEUTICSDirecteur général
1 distinct company in the disclosed relationships. Network coverage is a separate preview.
Explore relationship network
Evidence
Open a filing in the activity ledger to inspect its transactions, original regulatory document and source provenance.
Identify the affected field and a source that supports the correction. Use the private contact for rights requests; do not attach identity documents unless necessary and requested.
How to cite this record
OpenInsider. “Thibaut du Fayet”. Record insider:fr:amf:RS00005297%7CPERSON%7Cthibaut%20du%20fayet. https://openinsider.eu/en/insiders/insider%3Afr%3Aamf%3ARS00005297%257CPERSON%257Cthibaut%2520du%2520fayet Regulatory source: AMF. The official publication remains authoritative.
Profiles and figures may change with new filings and corrections. Record the period and access date when reusing a figure; this link is not a historical snapshot.